Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

Juwana, 2009 - sirolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis

HORIZONS-AMI Stent, 2008 - paclitaxel ES vs bare-metal stent

MISSION, 2008 - sirolimus ES vs bare-metal stent

DEDICATION, 2008 - drug ES vs bare-metal stent

Díaz de la Llera, 2007 - sirolimus ES vs bare-metal stent

SESAMI, 2007 - sirolimus ES vs bare-metal stent

TYPHOON, 2006 - sirolimus ES vs bare-metal stent

PROSIT, 2006 - sirolimus ES vs paclitaxel ES

HAAMU-STENT, 2006 - paclitaxel ES vs bare-metal stent

PASSION, 2006 - paclitaxel ES vs bare-metal stent

WEST, 2006 - systematic PCI (+stent) vs no systematic PCI

CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis

Di Lorenzo et al., 2005 - sirolimus ES vs paclitaxel ES

ZWOLLE 6, 2005 - primary stenting vs ballon angioplasty

CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI

senior PAMI, 2005 - primary PCI vs thrombolytic therapy

STOPAMI 3, 2004 - primary stenting vs ballon angioplasty

GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI

MERLIN (Sutton), 2004 - immediate systematic ballon angioplastyte vs no immediate angioplasty



See also:

  • All acute myocardial infarction clinical trials
  • All clinical trials of myocardial revascularization
  • All clinical trials of reteplase
    		•  

    RAPID-2 study, 1996

    Treatments

    Studied treatment 10 plus 10 megaunits double bolus of reteplase
    Control treatment front-loaded alteplase
    Concomittant treatment Aspirin IV heparin

    Patients

    Patients patients with acute myocardial infarction within 12h from onset of ischemic chest pain

    Method and design

    Randomized effectives 169 / 155 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 35 days
    Number of centre 25
    Geographic area USA, Germany
    Primary endpoint Patency at 90 min


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    short term death

    7 / 169
         13 / 155
         0,49 [0,20;1,21]

    stroke (fatal and non fatal)

    3 / 169
         4 / 155
         classic 0,69 [0,16;3,02]

    Major bleeding

    21 / 169
         15 / 155
         classic 1,28 [0,69;2,40]

    Haemmorhagic stroke

    2 / 169
         3 / 155
         classic 0,61 [0,10;3,61]

    reinfarction

    8 / 169
         7 / 155
         classic 1,05 [0,39;2,82]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    short term death 7 / 169 (4,1%) 13 / 155 (8,4%) 0,49 [0,20;1,21] at 35 days   
    stroke (fatal and non fatal) 3 / 169 (1,8%) 4 / 155 (2,6%) 0,69 [0,16;3,02] at 35 days   
    Major bleeding 21 / 169 (12,4%) 15 / 155 (9,7%) 1,28 [0,69;2,40] Bleedings requiring transfusions (excluding during surgery) at 35d   
    Haemmorhagic stroke 2 / 169 (1,2%) 3 / 155 (1,9%) 0,61 [0,10;3,61] Intracranial bleeding at 35 days   
    reinfarction 8 / 169 (4,7%) 7 / 155 (4,5%) 1,05 [0,39;2,82] at 35 days   
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    short term death 4,14% 8,39% -42,5‰
    stroke (fatal and non fatal) 1,78% 2,58% -8,1‰
    Major bleeding 12,43% 9,68% 2,7%
    Haemmorhagic stroke 1,18% 1,94% -7,5‰
    reinfarction 4,73% 4,52% 2,2‰


    Reference(s)

    Trials register # NA
    • Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, Chernoff R, Christie LG, Feldman RL, Seals AA, Weaver WD. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.. Circulation 1996;94:891-8
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend